CIK 0001661998 · Non-accelerated filer<br>Smaller reporting company
Q32 Bio Inc.
Sign in to watch- Ticker
- QTTB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473468154
- Phone
- 781-999-0232
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Former names
- Q32 Bio Inc., Homology Medicines, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $320,396
- in 6 filings
Net −$320,396. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-24 | GRAYZEL DAVID S. Director | Returned to the company · Stock Option (Right to Buy) | −2,569 | 0 | ||
| 2025-02-24 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +2,569 | 2,569 | ||
| 2025-02-24 | GRAYZEL DAVID S. Director | Returned to the company · Stock Option (Right to Buy) | −18,595 | 0 | ||
| 2025-02-24 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +18,595 | 18,595 | ||
| 2025-02-24 | Thistle Mary Director | Returned to the company · Stock Option (Right to Buy) | −12,767 | 0 | ||
| 2025-02-24 | Thistle Mary Director | Grant or award · Stock Option (Right to Buy) | +12,767 | 12,767 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Grant or award | +37,500 | 61,374 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −32,891 | 0 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +32,891 | 32,891 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −13,305 | 0 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +13,305 | 13,305 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −17,506 | 0 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +17,506 | 17,506 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −56,413 | 0 | ||
| 2025-02-24 | Violette Shelia M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +56,413 | 56,413 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Returned to the company · Stock Option (Right to Buy) | −2,013 | 0 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +2,013 | 2,013 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Returned to the company · Stock Option (Right to Buy) | −6,238 | 0 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +6,238 | 6,238 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Returned to the company · Stock Option (Right to Buy) | −2,880 | 0 |
Page 6 of 11 · 207 trades